Krystal Biotech Inc. stocks have been trading up by 5.91 percent amid strong optimism from positive gene-therapy pipeline news
Click Here for a Millionaire's POV on Trading KRYS
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
What Traders Need To Know
- BofA raised its price target on Krystal Biotech to $396 from $364 while reiterating a Buy rating, reflecting stronger long-term expectations for Vyjuvek ex-U.S. and increased confidence in KB801 for neurotrophic keratitis, despite slightly lower 2026 estimates.
- Jefferies raised its price target on Krystal Biotech from $399 to $474 while reiterating a Buy rating, citing expectations for another strong Q2 driven by sustained U.S. demand and increasing international revenue contribution.
- Recent weekly action shows KRYS holding in the mid-$300s, with a push to $362 after a sharp intraday range from roughly $335 to the mid-$350s.
- Strong margins, positive earnings, and a clean balance sheet give Krystal Biotech Inc. room to fund growth while analysts lean bullish on near-term demand and longer-term pipeline value.
Weekly Update Jul 13 – Jul 17, 2026: On Sunday, July 19, 2026 Krystal Biotech Inc. stock [NASDAQ: KRYS] is trending up by 5.91%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
Krystal Biotech (KRYS) has transitioned into a high-margin commercial rare-disease platform, with Q1 2026 revenue of $116.4M annualizing to ~30% of FY revenue and supporting exceptional 94% gross margin and ~46% operating margin run-rate. Profitability metrics (profit margin ~54%, ROE ~20%) are elite for biotech, while balance sheet strength is outstanding: current ratio 9.5, negligible leverage (debt/equity 0.01), and >$800M in cash and short-term investments. Valuation is rich (P/E 35, P/S 18.5), but justified by durable orphan exclusivity and pipeline optionality.
Technically, KRYS is in a clear short-term uptrend: the weekly series from 7/13–7/17 shows a rapid rebound from 338 to 362 after a brief shakeout, forming a higher low versus the 339–341 area and a strong weekly close near the top of the range. Intraday 5‑minute action (not shown in detail) has featured rising support with buyers stepping in on shallow pullbacks and expanding volume on up-swings. A precise trading level is $340: that zone now functions as key support and a logical stop reference for swing longs, with upside focus on a retest of the recent high near $363 and then the $380 area.
More Breaking News
- GIPR Slides As Generation Income Properties Fights Nasdaq Delisting
- ASTS Tumbles On $1B Convert As Piper Sandler Targets $100
- PMAX Edges Lower As Traders Digest Recent Spike
- Neuronetics Inc. STIM Slides As Weak Margins Pressure Stock
Fundamentally and relative to Healthcare and Biotech & Life Sciences benchmarks, Krystal screens as a top‑quartile grower with best‑in‑class margins and de‑risked lead asset, evidenced by back‑to‑back target hikes from BofA ($396) and Jefferies ($474) tied to stronger Vyjuvek ex‑U.S. and KB801 confidence. The stock warrants a premium multiple versus peers given profitability and pipeline; I set a 12‑18 month target range of $410–$440, with strong support at $335–$340 and major resistance around $380 then $400.
Quick Financial Overview
Krystal Biotech Inc. is printing real earnings power, which matters for traders in a high-valuation biotech. Quarterly revenue sits around $116.4M, translating to about $389.1M over the trailing year, and gross margin is an exceptional 94.2%. The latest quarter delivered net income of $55.9M and diluted EPS of $1.83, with profit margin above 50%, showing that the current Vyjuvek-driven model is not just a top-line story.
On valuation, KRYS trades at a price-to-sales ratio of 18.5 and a P/E near 35.1, rich but common for a high-growth, niche biotech with a commercial product and pipeline. Price-to-book around 6.05 and price-to-cash-flow near 24 show traders are already paying up for growth and execution. Return on equity above 19% and strong return on capital metrics support the idea that management is turning R&D and capital spend into real value.
Balance sheet strength backs the bullish analyst calls. Krystal Biotech Inc. carries minimal debt, with total debt-to-equity around 0.01 and a current ratio of 9.5, plus roughly $823.4M in cash and short-term investments and working capital near $911.9M. Recent operating cash flow of about $80.4M and free cash flow of $73.2M give KRYS solid self-funding capacity, important as it scales Vyjuvek and advances KB801 while Wall Street raises price targets.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.